Skip to content

Author

Changli Wang

We have 2 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial.

INTRODUCTION In the phase III RATIONALE-315 trial (NCT04379635), perioperative tislelizumab plus neoadjuvant chemotherapy significantly improved overall and event-free survival versus placebo plus chemotherapy in patients with resectable stage II-IIIA non-small cell lung cancer (NSCLC). Here, report prespecified patien...

D. Yue, F. Cappuzzo, Wen-Xiang Wang et al. · 0 citations
Open access Jul 2026

NSUN2-mediated m5C modification of E2F1 promotes lung adenocarcinoma progression via the RAD54L signaling axis.

This work identifies a hierarchical signaling axis driven by the RNA methyltransferase NSUN2 that fuels LUAD progression and establishes the NSUN2-E2F1-RAD54L axis as a critical driver of LUAD and a promising target for therapeutic intervention.

Yue Li, Chen Chen, Hailin Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.